Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Leukemia 19Leukemia, Promyelocytic, Acute 11Multiple Myeloma 8Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Blast Crisis 3Testicular Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Cytarabine 68fludarabine phosphate 59Peripheral Blood Stem Cell Transplantation 51Cyclophosphamide 48Busulfan 46Tacrolimus 36Mycophenolic Acid 35Etoposide 33Cyclosporine 32Methotrexate 29Whole-Body Irradiation 28Antilymphocyte Serum 28Filgrastim 27Flow Cytometry 22Mitoxantrone 19Radiotherapy 18Daunorubicin 18Melphalan 16Idarubicin 16sargramostim 13Gene Expression Profiling 12Clofarabine 12Polymerase Chain Reaction 11Methylprednisolone 11Decitabine 10Cord Blood Stem Cell Transplantation 10merphos 9Transplantation 9Immunologic Techniques 9Granulocyte Colony-Stimulating Factor 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Congenital Abnormalities × Arsenic Trioxide × Clear all
NCT00093483 2014-01-13

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Completed
61 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡